Skip to main content
SPTX logo

SPTX · Seaport Therapeutics, Inc.

Track SPTX — free
$18.14 -0.18 (-0.96%)
Market Cap
$980.14M
Shares
53.53M
Volume · Nov 19 63.59K Avg daily vol (3M) 252.84K

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$18.31 Open$18.19 Day$17.84–19.12 Available close range$15.25–27.84 Avg vol 30d266K Short int3.7M · 7.0% of shares · 17.4d Short vol85% Last earningsNov 2, 2026 DataMay 2026–Nov 2026 Filing10-Q · Nov 2

The closing range uses available history since May 1, 2026; less than a full year is stored.

Up next

Jan 15, 2027 Est · unconfirmed · in 8 wks

Latest documents

2026
Nov 10
Investor event
Cash runway into 2029 supports upcoming readouts

Seaport Therapeutics ended Q3 with just north of $403 million, providing runway into 2029 ahead of a Glyph Allo top-line readout in the first half of 2027 and a Glyph-Ago Phase 2A readout in early 2028.

3 source passages
Seaport Therapeutics ended Q3 with just north of $403 million on our balance sheet. That provides us runway into 2029, and as mentioned earlier, we covered three upcoming key clinical readouts. Our lead program, Glyph Allo, is currently in a Phase 2B potential registration-enabling study in MDD. Our second program, Glyph-Ago, we recently shared key proof-of-concept data, and we just dosed our patient in a Phase IIa trial in generalized anxiety disorder. We get through our top-line readout of our current trial in glyph-allo-buy one. That's in the first half of 2027, and then we move into our second program, glyph-ago. We get our Phase 2A readout in early 2028 and our Phase 2-3 potentially registration-enabling trial at the end of 2028. Open the document at this passage
Nov 2
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Cash runway extends into 2029 after IPO

Seaport Therapeutics reported a $114.4 million nine-month net loss and $403.8 million in cash, cash equivalents and investments, which management believes will fund operations into 2029 after its IPO.

Net loss $26.39M Diluted EPS -$0.49
Read from the MD&A section
3 source passages
During the nine months ended September 30, 2026 and 2025, we had a net loss of $114.4 million and $50.7 million, respectively. As of September 30, 2026, we had cash, cash equivalents and investments of $403.8 million. Based on our current operating plans, we believe that our existing cash, cash equivalents and investments will be sufficient to fund our operating expenses and capital expenditure requirements into 2029. Open the document at this passage
Nov 2
Current report 8-K
Q3 Net Loss $26.4 Million; Cash Funds Operations Into 2029

Seaport Therapeutics reported a third-quarter 2026 net loss of $26.4 million, versus $22.5 million a year earlier. Cash, cash equivalents and investments totaled $403.8 million at September 30, 2026, expected to fund operations into 2029.

Financial results
3 source passages
Net loss was $26.4 million for the third quarter of 2026, as compared to a net loss of $22.5 million for the third quarter of 2025. Cash, cash equivalents, and investments totaled $403.8 million as of September 30, 2026. Seaport expects its cash, cash equivalents, and investments to support its current operating plans into 2029. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$290.43M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+2,139.9%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
7.0%
Latest settlement · 17.4 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Neutral Sentiment Neutral Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 24.6 · elevated Equity put/call 0.72
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 50-day avg −9%
below
RSI (14) 40
neutral
MACD trend Negative
52-week position 24%
mid-range
Volume (OBV) Bullish div.
accumulating
Momentum
relative strength
Neutral
1-month return −7%
trailing
6-month return +1%
trailing
Relative strength +4%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Accumulating
+37% holders QoQ · +26 funds added
Insider flow Accumulating
Net +$99.3K over 90 days · 0% sells
Short interest Rising
6.97% of shares out · ▲ +0.4% MoM · 17.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
74 holders — 13F breadth
Squeeze score 77
high risk · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 74%
annualized · 1-yr
Max drawdown −42%
past year
ATR 8.1%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
2 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 50-day avg
−9% Bearish
RSI (14)
40 Neutral
MACD trend
Negative Bearish
52-week position
24% Neutral
Volume (OBV)
Bullish div. Bullish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Accumulating
+37% holders QoQ · +26 funds added
Insider flow Accumulating
Net +$99.3K over 90 days · 0% sells
Short interest Rising
6.97% of shares out · ▲ +0.4% MoM · 17.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
74 holders — 13F breadth
Price context
position in its available closing range
Range low $15 Now $18 · 24% Range high $28
vs 50-day avg -9%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Cash, cash equivalents, and investments 427.3M as of June 30, 2026 —
Glyph2BLSD 1.62M the three months ended June 30, 2026 filing —
Glyph2BLSD direct research and development expenses 1.62M the three months ended June 30, 2026 filing —
GlyphAgo 3.48M the three months ended June 30, 2026 filing —
GlyphAgo direct research and development expenses 3.48M the three months ended June 30, 2026 filing —
GlyphAllo 12.8M the three months ended June 30, 2026 filing —
GlyphAllo direct research and development expenses 12.8M the three months ended June 30, 2026 filing —
Gross proceeds from IPO 260M May 2026 —
Preclinical and early discovery assets 1.41M the three months ended June 30, 2026 filing —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
SPTX
Seaport Therapeutics, Inc.
this stock
$980.14M — — — 7.0%
VRTX
Vertex Pharmaceuticals Inc
$136.01B +18.3% +46.2% 34.5 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$97.81B +22.5% +20.8% 20.9 2.1%
MRNA
Moderna, Inc.
$79.63B +567.3% +4.3% — 8.2%
CSLLY
Csl Ltd
$63.15B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
74
% held
71.3%
Net QoQ
+668.2K sh
Top holder
ARCH Venture Management,…
Held Float
View
Held by Funds
Fund positions
44
View
Short & Settlement
Short Interest Rising
Shares short
3.7M
Days to cover
17.4d
Change
+14.5K sh
View
Short Volume
Short vol %
85%
As of
Nov 18, 2026
Short Total
View
Fails to Deliver
FTD shares
4
Value
$84
As of
Oct 30, 2026
View
Off-Exchange
Off-exchange %
32.5%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net buying
Net (90d)
+$99.3K
Buyers / Sellers
1 / 0
Buyers Sellers
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Nov 10, 2026
This year
12

Seaport Therapeutics ended Q3 with just north of $403 million, providing runway into 2029 ahead of a Glyph Allo top-line readout in the first half of 2027 and a Glyph-Ago Phase 2A readout in early 2028.

View
Exempt Offerings
Offering
$226.0M
Filed
Oct 31, 2024
View
Earnings & Events
Webcasts
Last webcast
Nov 10, 2026
View
Investor Relations
Latest news
Seaport Therapeutics Reports Thir…
Published
Nov 2, 2026
View

Performance

5D 20D 120D MTD YTD
SPTX -14.1% -7.2% +0.7% -6.6% —
SPY -3.9% -5.6% -3.5% -3.4% +7.1%
vs SPY -10.2% -1.7% +4.1% -3.2% —
Key facts CIK 2042347 CUSIP 81221K108 13F (30d) 73 filings 73 filers Visit website Investor relations